Restoring Dopaminergic Function
NeuroDP Therapeutics Inc. is developing next-generation gene therapies targeting lysosomal function to protect dopaminergic neurons and restore hope for patients worldwide.
OUR MISSION
Rewriting the Future
of
Neurodegenerative Disease
NeuroDP Therapeutics is dedicated to transforming the lives of patients through targeted AAV gene therapies. By integrating neurological research with AI-driven bioprocessing, we aim to reverse the progression of neurodegeneration.
Precision Genetic Delivery
The Integrated Development Platform at NeuroDP Therapeutics leverages proprietary AAV technology to deliver precision genetic payloads directly to dopaminergic neurons, bypassing the blood-brain barrier with unparalleled efficiency.
- Integrated AI Modeling & Optimization
- Cell-Specific Enhanced Promoters
- Scalable AAV Bioprocessing System
- Advanced BBB Crossing Technology
Pipeline Strategy & Research
Strategic Development
NDP-101 Program
A novel AAV candidate focused on preventing synaptic degradation in early-stage models of Parkinson's disease by enhancing neuronal resilience. (Dual AAV Vector)
Strategic Development
NDP-102 Program
Designed for lysosomal rescue to restore enzymatic activity and clear toxic protein aggregates, targeting the primary drivers of neurodegeneration.
People in NeuroDP
Uniting world-class expertise in AAV gene therapy and biotechnology to redefine the therapeutic landscape for neurodegeneration.
DrPark CDMO
Leading AAV manufacturing and process development, specializing in clinical-grade vector production and scalable bioprocessing solutions.
Team NSPX
Targeted genetics team focused on neuro-specific payload optimization and bioinformatics for precise therapeutic delivery.
Team H Biomarker
Advancing clinical diagnostics through quantitative lysosomal function assays and novel biomarkers for disease monitoring.
Begin Conversation
Long Term Vision
We envision a future where Parkinson’s is no longer a terminal diagnosis. Our goal is to scale our integrated bioprocessing platform globally, ensuring that functional neurodegeneration reversal is accessible to all who need it, setting a new standard for regenerative medicine.
contact@ndptherapeutics.com
Headquarters
Delaware, USA